Challenges in production of recombinant proteins
β Scribed by Gen Larsson
- Publisher
- Springer
- Year
- 2007
- Tongue
- English
- Weight
- 81 KB
- Volume
- 31
- Category
- Article
- ISSN
- 1615-7605
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The advantages of serum-free culture for the manufacture of recombinant biopharmaceuticals from mammalian cells are reviewed. The process favoured is fed-batch serum-free cell culture. This process is applicable to the majority of cell lines, is practical on the large scale, gives the lowest manufac
Recombinant proteins that have survived the challenges of process development and clinical trials are becoming blockbuster medical products. Growth factors, enzymes and antibodies are being improved by mutational approaches, fused with other proteins, and even chemically modified in vitro. Drug deve
This review is based on our recent experience in producing the first commercial recombinant proteins in transgenic plants. We bring forward the issues that have to be considered in the process of selecting and developing a winning transgenic plant production system. From the production point of view
## Abstract Global demand for recombinant proteins has steadily accelerated for the last 20 years. These recombinant proteins have a wide range of important applications, including vaccines and therapeutics for human and animal health, industrial enzymes, new materials and components of novel nanoβ